Siplizumab

Siplizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized(fromrat)
Target	CD2
Clinical data
ATC code	none;
Identifiers
CAS Number	288392-69-8;
ChemSpider	none;
UNII	KUW1QG1ZM3;
KEGG	D05847;
	(what is this?)(verify)

Siplizumab(MEDI-507) is an investigationalmonoclonal antibodywith a humanIgG1,kappa directed toCD2.The agent has shown potentimmunomodulatoryeffects, selectively suppressing the function ofTandNK cells,and has been tested as a possible treatment forpsoriasisand in the prevention ofgraft-versus-host disease.^[1]^[2]^[3]^[4]^[5]

References

^Podestà, Manuel A.; Binder, Christian; Sellberg, Felix; DeWolf, Susan; Shonts, Brittany; Ho, Siu-Hong; Obradovic, Aleksandar; Waffarn, Elizabeth; Danzl, Nichole; Berglund, David; Sykes, Megan (January 2020)."Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro".American Journal of Transplantation.20(1): 88–100.doi:10.1111/ajt.15533.PMC6940533.PMID 31319439.
^Langley, Richard G.; Papp, Kim; Bissonnette, Robert; Toth, Darryl; Matheson, Robert; Hultquist, Micki; White, Barbara (July 2010). "Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies".International Journal of Dermatology.49(7): 818–828.doi:10.1111/j.1365-4632.2010.04512.x.PMID 20618506.S2CID 21145758.
^O'Mahony, Deirdre; Morris, John C.; Stetler-Stevenson, Maryalice; Matthews, Helen; Brown, Margaret R.; Fleisher, Thomas; Pittaluga, Stefania; Raffeld, Mark; Albert, Paul S.; Reitsma, Dirk; Kaucic, Karen; Hammershaimb, Luz; Waldmann, Thomas A.; Janik, John E. (1 April 2009)."EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies".Clinical Cancer Research.15(7): 2514–2522.doi:10.1158/1078-0432.CCR-08-1254.PMC7322623.PMID 19293260.
^Adkins, Douglas; Ratanatharathorn, Voravit; Yang, Harry; White, Barbara (27 July 2009)."Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease".Transplantation.88(2): 198–202.doi:10.1097/TP.0b013e3181abfbf7.PMID 19623014.
^Cvetkovski, Filip; Razavi, Ronia; Sellberg, Felix; Berglund, Erik; Berglund, David (October 2023)."Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro".American Journal of Transplantation.23(10): 1603–1611.doi:10.1016/j.ajt.2023.05.032.PMID 37270108.

Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it.

Thisantineoplasticorimmunomodulatory drugarticle is astub.You can help Wikipedia byexpanding it.

[1] Podestà, Manuel A.; Binder, Christian; Sellberg, Felix; DeWolf, Susan; Shonts, Brittany; Ho, Siu-Hong; Obradovic, Aleksandar; Waffarn, Elizabeth; Danzl, Nichole; Berglund, David; Sykes, Megan (January 2020)."Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro".American Journal of Transplantation.20(1): 88–100.doi:10.1111/ajt.15533.PMC6940533.PMID 31319439.

[2] Langley, Richard G.; Papp, Kim; Bissonnette, Robert; Toth, Darryl; Matheson, Robert; Hultquist, Micki; White, Barbara (July 2010). "Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies".International Journal of Dermatology.49(7): 818–828.doi:10.1111/j.1365-4632.2010.04512.x.PMID 20618506.S2CID 21145758.

[3] O'Mahony, Deirdre; Morris, John C.; Stetler-Stevenson, Maryalice; Matthews, Helen; Brown, Margaret R.; Fleisher, Thomas; Pittaluga, Stefania; Raffeld, Mark; Albert, Paul S.; Reitsma, Dirk; Kaucic, Karen; Hammershaimb, Luz; Waldmann, Thomas A.; Janik, John E. (1 April 2009)."EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies".Clinical Cancer Research.15(7): 2514–2522.doi:10.1158/1078-0432.CCR-08-1254.PMC7322623.PMID 19293260.

[4] Adkins, Douglas; Ratanatharathorn, Voravit; Yang, Harry; White, Barbara (27 July 2009)."Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease".Transplantation.88(2): 198–202.doi:10.1097/TP.0b013e3181abfbf7.PMID 19623014.

[5] Cvetkovski, Filip; Razavi, Ronia; Sellberg, Felix; Berglund, Erik; Berglund, David (October 2023)."Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro".American Journal of Transplantation.23(10): 1603–1611.doi:10.1016/j.ajt.2023.05.032.PMID 37270108.

[1]

[2]

[3]

[4]

[5]